Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5

Journal of Clinical Oncology

Volumn 20, Issue 24, 2002, Pages 4621-4627

  Jakesz, Raimund ^a   Hausmaninger, Hubert ^a   Kubista, Ernst ^a   Gnant, Michael ^a   Menzel, Christian ^a   Bauernhofer, Thomas ^a   Seifert, Michael ^a   Haider, Karin ^a   Mlineritsch, Brigitte ^a   Steindorfer, Peter ^a   Kwasny, Werner ^a   Fridrik, Michael ^a   Steger, Guenther ^a   Wette, Viktor ^a   Samonigg, Hellmut ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; GOSERELIN; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; FEMALE; FEVER; HORMONAL REGULATION; HORMONE RESPONSE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PREMENOPAUSE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; STOMATITIS; SURVIVAL RATE; VERTIGO;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; GOSERELIN; HUMANS; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; OVARIECTOMY; PREMENOPAUSE; SURVIVAL RATE; TAMOXIFEN;

EID: 0037115687     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.09.112     Document Type: Article

References (30)

1. Bonadonna G, Valagussa P, Zambetti M, et al: The Milan experience with adjuvant chemotherapy in premenopausal breast cancer. Recent Res Cancer Res 115:113-117, 1989
2. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
3. Pagani O, O'Neill A, Castiglione M, et al: Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632-640, 1998
4. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
5. Chlebowski RT, Collyar DE, Somerfield MR, et al: American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene. J Clin Oncol 17:1939-1955, 1999
6. Early Breast Cancer Trialists' Collaborative Group: Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 348:1189-1196, 1996
7. Jakesz R, Samonigg H, Gnant M, et al: Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Eur J Cancer 34:66-70, 1998
8. Jakesz R, Hausmaninger H, Haider K, et al: Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. J Clin Oncol 17:1701-1709, 1999
9. Bloom HJ, Richardson WW: Histologic grading and prognosis in breast cancer. Br J Cancer 11:359-377, 1957
10. Reiner A, Neumeister B, Spona J, et al: Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50:7057-7061, 1990
11. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
14. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc B 34:187-220, 1972
15. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-1692, 1988
16. Goldhirsch A, Gelber RD, Castiglione M: The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: The International Breast Cancer Study Group. Ann Oncol 1:183-188, 1990
17. Bianco AR, Del Mastro L, Gallo C, et al: Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 63:799-803, 1991
18. Davidson NE: Combined endocrine therapy for breast cancer: New life for an old idea? J Natl Cancer Inst 92:859-860, 2000
19. Gelber RD, Goldhirsch A, Castiglione M, et al: Premenopausal oopherectomy versus CMF chemotherapy in stage II breast carcinoma: The International Breast Cancer Study Group. Lancet 342:305, 1993 (letter)
20. Ejlertsen B, Dombernowsky P, Mouridsen HT, et al: Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). Proc Am Soc Clin Oncol 18:66a, 1999 (abstr 248)
21. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Lancet 341:1293-1298, 1993
22. Davidson NE, O'Neill A, Vukov A, et al: Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Proc Am Soc Clin Oncol 18:67a, 1999 (abstr 249)
23. Taylor CW, Green S, Dalton WS, et al: Multicenter randomized trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study. J Clin Oncol 16:994-999, 1998
24. Klijn JGM, Beex LVAM, Mauriac L, et al: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 92:903-911, 2000
25. Boccardo P, Rubagotti A, Amoroso D, et al: Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18:2718-2727, 2000
26. Roché HH, Kerbrat P, Bonneterre J, et al: Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients (pts) with positive hormone-receptor (HR+) and 1-3 node-positive (N+) tumor: Results of the FASG 06 trial. Proc Am Soc Clin Oncol 19:72a, 2000 (abstr 279)
27. Baum M, Rutgers EE: Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomized trial by the Cancer Res Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group and the Gruppo Interdisciplinare Valutazione in Interventi in Oncologia. Breast 8:233, 1999 (abstr)
28. Jonat W: Zoladex™ (goserelin) vs. CMF as adjuvant therapy in pre-/perimenopausal node-positive breast cancer: Preliminary efficacy results from the ZEBRA Study. Eur J Cancer 36:S67, 2000 (suppl 5, abstr)
29. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
30. Goldhirsch A, Gelber RD, Price KN, et al: Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 343:377-381, 1994